

ASHP Alabama Residency Conference 2024

Program Information and CPE Credit Survey Links

April 4, 2024, 12 Noon CDT



Alabama Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants must pre-register, participate in the entire presentation, and complete the online course evaluation to receive continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 60 days for participants who have successfully completed all requirements. There is no fee for ALSHP members to participate in this activity. Non-members fee: \$25, which is refundable when joining ALSHP within 30 days of the program date. Participants in this activity are subject to the [Terms and Conditions](#) for ALSHP meetings and events. Contact mail@alshp.org for questions about this CPE activity. These knowledge-based activities are intended for pharmacists. All sessions approved for 1 hour ACPE accredited continuing pharmacy education.

Session Number/ Time/Link to CPE Evaluation	Presenters	At the completion of these activities, the participants will be able to:	UAN
Room 1-1 12:05 https://www.surveymonkey.com/r/ARC24_1-1	Jacee Billings Blake Christensen Morgan Pierce Jessica Salvatore	<ul style="list-style-type: none"> -Describe current guidance for assessing patients on dementia medications -Recognize the use of time in program as an indicator of treatment success in residential treatment programs -Discuss current recommendations on how to reduce readmission rates among vulnerable populations -Explain the opioid drug-drug interaction with naltrexone 	0172-0000-24-013-L01-P
Room 1-2 13:05 https://www.surveymonkey.com/r/ARC24_1-2	Matthey Hadley Madison Sanders Christian Hardrick Allison Burdick	<ul style="list-style-type: none"> -Identify an appropriate administration time of long-acting subcutaneous insulin in the management of diabetic ketoacidosis -Discuss the relationship between dexmedetomidine and new-onset atrial fibrillation (NOAF) in critically ill patients -Identify the beneficial outcomes of having an emergency medicine pharmacist actively involved in sepsis management -Discuss the impact an emergency medicine pharmacist can have on post-intubation sedation selection and associated patient outcomes 	0172-0000-24-014-L01-P
Room 1-3 14:15 https://www.surveymonkey.com/r/ARC24_1-3	Ifeoma Ugwuegbulam Sandi Perry Erin Harrell Julia Goudeau	<ul style="list-style-type: none"> -Compare the mortality rate for early-onset sepsis in preterm neonates versus term neonates -Discuss the impact of a pharmacy-led penicillin allergy assessment protocol based on results of a retrospective chart review -Discuss the medication treatment of patients with hyperkalemia -Describe how timing of venous thromboembolism (VTE) prophylaxis impacts patient outcomes post craniotomy 	0172-0000-24-015-L01-P

		or craniectomy for traumatic brain injury	
Room 1-4 15:25 https://www.surveymonkey.com/r/ARC24_1-4	Kate Dorsten Ansley Carroll Maggie Goode David Sharogradsky	-Identify patient outcomes that may improve when utilizing methicillin-resistant Staphylococcus aureus (MRSA) nasal polymerase chain reaction (PCR) testing -Define the role of sodium bicarbonate administration during inpatient cardiac arrest events -Differentiate opioid consumption trends between groups receiving opioids only and multi-modal pain regimens -Identify key steps, error types, and antimicrobials involved in medication errors across the healthcare system.	0172-0000-24-016-L01-P
Room 2-1 12:05 https://www.surveymonkey.com/r/ARC24_2-1	Mallory McClung Joel Kennedy Cameron Crawford Gregory Taylor	-Identify the efficacy and safety differences between intravenous (IV) as needed (PRN) labetalol and hydralazine in acute blood pressure (BP) management -Determine if enteral midodrine assists in weaning intravenous (IV) vasopressors in patients with septic shock -Review patient risk factors and consider how narrower antibiotics can provide reliable coverage and reserve use of broad spectrum antimicrobials -Describe how the initial loop diuretic strategy affects time to decongestion in acute decompensated heart failure (ADHF)	0172-0000-24-017-L01-P
Room 2-2 13:05 https://www.surveymonkey.com/r/ARC24_2-2	Christa Kooser J.D. Olivet Tilyn Digiacomio Alana Shunnarah	-Discuss the role a D10W infusion can play on hyperkalemia prevention in nondiabetic, hemodialysis patients -Describe the safety and efficacy of linezolid for switch therapy in gram positive bacteremia treatment -Compare the differences in hemostatic control, time to administration, and thrombosis between four-factor prothrombin complex concentrate and andexanet alfa -Evaluate strategies used to de-label inaccurate beta-lactam allergies in the inpatient setting	0172-0000-24-018-L01-P
Room 2-3 14:15 https://www.surveymonkey.com/r/ARC24_2-3	Stephanie Waldrep Kyle Humphreys Victoria Burnette Vindhya Basetty	-Discuss the clinical outcomes of using high-dose micafungin versus standard-dose micafungin in treating candidemia in obese patients -Describe how pharmacist to patient ratio impacts patient outcomes at large, academic medical center -Identify risk factors for the development of cytomegalovirus in kidney transplant recipients -Discuss the prevalence of polypharmacy in VIVA MEDICARE individuals 65 years of age or older with a diagnosis of chronic kidney disease that could benefit from deprescribing proton pump inhibitors (PPIs) and/or oral antidiabetic agents (OADs).	0172-0000-24-019-L01-P

<p>Room 2-4 15:25 https://www.surveymonkey.com/r/ARC24_2-4</p>	<p>Alexa Allen Lori Cheng Lauren Holbrook Devin Tully</p>	<ul style="list-style-type: none"> -Discuss how current VA trough-only kinetic dosing aligns with estimated AUC based dosing from an AUC dosing calculator -Explain the impact of Academic Detailing on the utilization of guideline directed medical therapy (GDMT) in heart failure patients -Explain the impact of pharmacist recommendations on medication therapy based on pharmacogenomic test results -Identify the effects of a standardized order set on appropriate prescribing of supplemental chemotherapy medications 	<p>0172-0000-24-020-L01-P</p>
<p>Room 3-1 12:05 https://www.surveymonkey.com/r/ARC24_3-1</p>	<p>Danielle Wilson Joseph Lawson Andrew Norton Janelle Trosclair</p>	<ul style="list-style-type: none"> -Discuss adherence to current guidelines and evidence-based literature for the management of moderate and severe traumatic brain injury -Discuss the extent of intravenous to oral antibiotic conversions in patients with eligible osteomyelitis or gramnegative bloodstream infections -Recognize the benefit of pharmacy technicians in a medication history program to decrease medication errors -List possible benefits of a subcutaneous insulin protocol for mild to moderate diabetic ketoacidosis (DKA) 	<p>0172-0000-24-021-L01-P</p>
<p>Room 3-2 13:05 https://www.surveymonkey.com/r/ARC24_3-2</p>	<p>Turner Huddleston Anna Armstrong Jasmine Morgan Steven Fruehwald</p>	<ul style="list-style-type: none"> -Evaluate the appropriateness of Heparin Induced Thrombocytopenia (HIT) antibody test orders and apply evidence-based HIT management -Evaluate the impact of nirsevimab on rates and severity of RSV infection at a large pediatric hospital -Discuss the impact of BKV infection on outcomes in pediatric kidney transplant recipients -Evaluate a management strategy for BKV infection in pediatric kidney transplant recipients -Recall the mechanism of action for ketorolac and its role in pain management -Identify commonly used ketorolac dosing strategies and risks of acute kidney injury 	<p>0172-0000-24-022-L01-P</p>
<p>Room 3-3 14:15 https://www.surveymonkey.com/r/ARC24_3-3</p>	<p>Randy Hooks Rachel Friend Samantha Sims Kristie Sanchez</p>	<ul style="list-style-type: none"> -Discuss the appropriateness of fluid resuscitation in patients with septic shock -Discuss the strengths and limitations of utilizing dalbavancin for gram-positive bacteremia and osteomyelitis -Describe the difference in Anti-factor Xa (anti-Xa) heparin assay and activated partial thromboplastin time (aPTT) levels for heparin monitoring 	<p>0172-0000-24-023-L01-P</p>

		-Describe the difference in clinical inertia among patients with type 2 diabetes managed in different care models	
Room 3-4 15:25 https://www.surveymonkey.com/r/ARC24_3-4	Alyssa Barnes Lauren McConnell Andrew Gwaltney Kristin Hendricks	-Explain the importance of up-titrating glucagon-like peptide-1 receptor agonists (GLP-1 RAs) from their starting dose -Discuss the impact of conducting Medicare Annual Wellness Visits (MAWVs) in-person versus via telehealth on financial and clinical outcomes in a family medicine clinic -Discuss preliminary data from a multicenter retrospective project of cisatracurium vs atracurium in acute respiratory distress syndrome (ARDS) -Discuss the efficacy and safety of apixaban and warfarin in the treatment of venous thromboembolism in patients with severe renal impairment	0172-0000-24-024-L01-P